Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600134818) titled 'Efficacy Trial of Tirzepatide in Guangxi Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Complicated with Obesity and Construction of a Therapeutic Efficacy Prediction Model' on Oct. 21.
Study Type: Interventional study
Study Design:
Non randomized control
Primary Sponsor: Liuzhou Worker's Hospital
Condition:
Obesity combined with metabolic dysfunction associated-steatotic liver disease
Intervention:
Tepolpeptide treatment group:Tepolpeptide treatment
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-10-30
Target Sample Size: Tepolpeptide treatm...